The Zhitong Finance App learned that Kingsley Biotech (01548) is now up nearly 5%. As of press release, it has risen 4.75% to HK$13.22, with a turnover of HK$840.661 million.
According to the news, Legendary Biotech announced on April 5 that the US Food and Drug Administration (FDA) has approved CARVYKTI (Sidakiolenol) to treat patients with recurrent or refractory multiple myeloma (RRMM). These patients have received at least first-line treatment (including proteasome inhibitors and immunomodulators) and are resistant to lenalidomide.
According to Guolian Securities, considering that CARVYKTI recorded sales of 500 million US dollars in the MM terminal (4+ line) treatment in 2023, it is believed that as CARVYKTI is approved for second-line treatment and legendary Biotech and Johnson further expand the supply of European and American cell therapy production capacity in 2024, CARVYKTI is expected to accelerate commercialization.